Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

indium In 111 ibritumomab tiuxetan

Known as: In 111 Ibritumomab Tiuxetan, In111 ibritumomab tiuxetan, Indium In-111 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to detect certain types of B-cell non-Hodgkin lymphoma and is being studied in the detection of other… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Antibody-based therapeutic approaches have had a significant impact in the treatment of non-Hodgkin’s lymphoma (NHL). Rituximab’s… Expand
  • table I
  • figure 1
  • table II
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PurposePositron emission tomography (PET) with 89Zr-ibritumomab tiuxetan can be used to monitor biodistribution of 90Y… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2009
2009
Antibody-based therapies, both unconjugated antibodies and radioimmunotherapy, have had a significant impact on the treatment of… Expand
Is this relevant?
2008
2008
BACKGROUND A prospective, single-arm, open-label, nonrandomized Phase 2 study of combined fludarabine and mitoxantrone (FM) plus… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
We retrospectively evaluated our single-center clinical experience with 90Y-ibritumomab tiuxetan and 131I-tositumomab for therapy… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 3
Is this relevant?
2006
2006
Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin), a radiolabeled monoclonal antibody against the CD20 antigen, is indicated for… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
We report updated time-to-event variables of a phase III randomized study comparing yttrium 90-labeled ibritumomab with rituximab… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab… Expand
Is this relevant?
Review
2002
Review
2002
90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic agent recently approved for the treatment of relapsed or refractory… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2002
2002
PURPOSE Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceutical, San Diego, CA) is an effective therapy for patients… Expand
Is this relevant?